Adastra Holdings Ltd. (OTCPK:XTXXF) (CSE:XTRX)(FRA:D2EP) has been served with a civil claim filed in the Supreme Court of British Columbia pursuant to the Class Proceedings Act, R.S.B.C. 1996, c. 50 alleging that the company's press release of February 22, 2023 misstated certain material facts which mislead the plaintiff in the claim. The suit also names the company's subsidiary Adastra Labs Inc. and the company's CEO Michael Forbes.

The press release was regarding its receipt of Health Canada approval for the amendment to include cocaine under its controlled substances license, and Adastra also released a clarification of that press release.

The company denies the allegations in the claim and specifically that the press release was misleading and intends to vigorously …

Full story available on